


Preclinical Development HANDBOOK

Toxicology



Edited by
Shayne Cox Gad

CONTENTS

| | |
|--|-------------|
| Preface | xiii |
| 1 Preclinical Drug Development Planning <i>Nirmala Bhogal, Robert Combes, and Michael Balls</i> | 1 |
| 2 Use of Project Teams in Preclinical Development <i>Dorothy M. K. Keefe, Joanne M. Bowen, and Rachel J. Gibson</i> | 65 |
| 3 Relationship between Animal Models and Clinical Research: Using Mucositis as a Practical Example <i>Rachel J. Gibson, Joanne M. Bowen, and Dorothy M. K. Keefe</i> | 81 |
| 4 Bacterial Mutation Assay <i>Premkumar Kumpati</i> | 109 |
| 5 In Vitro Mammalian Cell Mutation Assays <i>C. Anita H. Bigger, Martha M. Moore, and Robert H. Heflich</i> | 129 |
| 6 In Vitro Mammalian Cytogenetic Tests <i>R. Julian Preston</i> | 155 |
| 7 In Vivo Genotoxicity Assays <i>Andreas Hartmann, Krista L. Dobo, and Hans-Jörg Martus</i> | 169 |
| 8 Repeat Dose Toxicity Studies <i>Shayne Cox Gad</i> | 213 |
| 9 Irritation and Local Tissue Tolerance Studies in Pharmaceutical Safety Assessment <i>Shayne Cox Gad</i> | 233 |
| 10 Safety Assessment Studies: Immunotoxicity <i>Jacques Descotes</i> | 269 |

| | | |
|-----------|---|------------|
| 11 | Immunotoxicity Testing: ICH Guideline S8 and Related Aspects | 323 |
| | <i>Hans-Gerd Pauels and John Taylor</i> | |
| 12 | Reproductive and Developmental Toxicology | 363 |
| | <i>Ronald D. Hood and Robert M. Parker</i> | |
| 13 | Carcinogenicity Studies | 423 |
| | <i>Shayne Cox Gad</i> | |
| 14 | Toxicokinetics: An Integral Component of Preclinical Toxicity Studies | 459 |
| | <i>Sonu Sundd Singh</i> | |
| 15 | <i>In Vitro</i> Toxicokinetics and Dynamics: Modeling and Interpretation of Toxicity Data | 509 |
| | <i>Arie Bruinink</i> | |
| 16 | Toxicologic Pathology | 551 |
| | <i>Paul B. Tchounwou and José A. Centeno</i> | |
| 17 | Secondary Pharmacodynamic Studies and <i>In Vitro</i> Pharmacological Profiling | 581 |
| | <i>Duncan Armstrong, Jacques Migeon, Michael G. Rolf, Joanne Bowes, Mark Crawford, and Jean-Pierre Valentin</i> | |
| 18 | Current Practices in Safety Pharmacology | 611 |
| | <i>Alan S. Bass, Peter K. S. Siegl, Gary A. Gintant, Dennis J. Murphy, and Roger D. Porsolt</i> | |
| 19 | Safety Assessment of Biotechnology-Derived Therapeutics | 695 |
| | <i>Mary Ellen Cosenza</i> | |
| 20 | Preclinical Development of Protein Pharmaceuticals: An Overview | 713 |
| | <i>Dipankar Das and Mavanur R. Suresh</i> | |
| 21 | The Pharmacogenomics of Personalized Medicine | 741 |
| | <i>Ronald E. Reid</i> | |
| 22 | Genomics | 801 |
| | <i>Dimitri Semizarov and Eric A. G. Blomme</i> | |
| 23 | Proteomics | 839 |
| | <i>Juan Casado and J. Ignacio Casal</i> | |
| 24 | Toxicogenomics in Preclinical Development | 867 |
| | <i>Eric A. G. Blomme, Dimitri Semizarov, and Jeffrey F. Waring</i> | |
| 25 | Toxicoproteomics: Preclinical Studies | 911 |
| | <i>B. Alex Merrick and Maribel E. Bruno</i> | |
| 26 | Regulatory Considerations | 945 |
| | <i>Evan B. Siegel and Duane B. Lakings</i> | |
| 27 | Regulatory Issues in Preclinical Safety Studies (U.S. FDA) | 965 |
| | <i>Kenneth L. Hastings and William J. Brock</i> | |

- 28 Selection and Utilization of CROs for Safety Assessment 979**
Joanne R. Kopplin and Ward R. Richter
- 29 Auditing and Inspecting Preclinical Research and Compliance with
Good Laboratory Practice (GLP) 993**
N. J. Dent
- 30 Drug Impurities and Degradants and Their Safety Qualification 1015**
Robin C. Guy
- 31 Bridging Studies in Preclinical Pharmaceutical Safety Assessment 1047**
Shayne Cox Gad
- Index 1053**